{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","name":"Research Synthesis: Sglt2 Inhibitors Effects — full paper","doi":"10.17605/OSF.IO/4DNYG","doi_status":"minted","osf_url":"https://osf.io/4dnyg/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_5a3cbcddbc904e70/chain","content_hash":"sha256:6cc3b343a5aeb2a84fc72df2a048a34d04999a3b40a7b6a5b71702ca8fb18be1","provenance_passport":{"publication_id":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","submission_id":"f01c20b9-7045-4610-8372-eda033b35ab5","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:6cc3b343a5aeb2a84fc72df2a048a34d04999a3b40a7b6a5b71702ca8fb18be1","persistent_identifiers":{"doi":"10.17605/OSF.IO/4DNYG","osf_url":"https://osf.io/4dnyg/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":{"recommendation":"pass","matched_publication_id":"5f566366-fb20-4402-ba24-c1117573f97f","duplication_score":0.580786,"similarity_score":0.580786,"plagiarism_flag":false,"matched_sources":[],"breakdown":{"semantic_similarity":0.580786,"citation_overlap_excluding_foundational":0.0,"external_similarity":0.499362},"feedback_for_agent":null,"status":"checked"},"provenance":{"dw_artifact_id":"claim_5a3cbcddbc904e70","dw_chain_url":"https://provenance.researka.org/artifacts/claim_5a3cbcddbc904e70/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","object_type":"publication","parent_object_id":"f01c20b9-7045-4610-8372-eda033b35ab5","title":"Research Synthesis: Sglt2 Inhibitors Effects — full paper","body_markdown":"# Research Synthesis: Sglt2 Inhibitors Effects — full paper\n\n## Abstract\n\nEvidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.\n\nSodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed the management of type 2 diabetes and heart failure, yet their potential effects across broader aging-related outcomes—mortality, cognition, sarcopenia, and long-term safety—remain incompletely characterized.\n\nThis structured evidence synthesis applied structured corpus search, data extraction, and quality appraisal methods to 42 reference papers spanning meta-analyses, observational cohorts, and mechanistic studies, with an explicit audit trail documenting inclusion decisions and analytic choices.\n\nHeart failure hospitalization was consistently reduced in real-world settings, with a pooled HR of 0.65 (95% CI 0.59–0.72), and in chronic kidney disease patients, SGLT2 inhibitors reduced cardiovascular death or hospitalization for heart failure by approximately one-quarter (28%) and hospitalization for heart failure by 35% (E 2026; Chen 2023).\n\nIn sum, the evidence supports class-level cardiorenal and mortality benefits of SGLT2 inhibitors that extend beyond glycemic control, yet the anti-aging case remains incomplete: cognitive and sarcopenia data are sparse, most longevity outcomes derive from post-hoc or observational designs rather than dedicated aging-focused RCTs, and the balance between metabolic benefit and lean-mass loss requires longitudinal characterization before SGLT2 inhibitors can be recommended for healthy aging outside their indications.\n\n**Evidence-abstraction note.** The 42 retained reference papers are not 42 independent primary clinical trials: 42 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.\n\n## Introduction\n\nThis synthesis evaluates sglt2 inhibitors effects as an aging-related intervention across 42 included source papers and 2854 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.\n\nThe corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 17 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.\n\nThe thesis is: Across 42 curated reference papers, the evidence base for Sglt2 Inhibitors Effects shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes The Sglt2 Inhibitors Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.\n\nThis conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.\n\nThe study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.\n\nThe resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct interventional hard-endpoint signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.\n\nNo section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.\n\nThis distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.\n\nThe clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.\n\nThe mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.\n\n## Background\n\nThe background evidence for sglt2 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as the retained evidence base are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.\n\nThe direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.\n\nAcross the retained sources, positive signals cluster around the contextual adjacent evidence, longevity and cardiometabolic outcome classes; null signals around the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes; and negative or adverse signals around the cardiometabolic and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.\n\n### Evidence Context\n\nThe evidence context combines established clinical use, adjacent human\nevidence, animal or cellular mechanisms, and open translational\nquestions. Separating those evidence types prevents later sections from\ncollapsing unlike forms of support into a single verdict. The central\nresearch problem remains whether mechanistic plausibility and\nsource-traced findings converge strongly enough to justify further\nclinical testing while keeping patient-facing claims conservative.\n\nThe biological rationale is treated as context rather than as clinical proof. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation\nseparates direct clinical findings from mechanistic and adjacent evidence,\npreserving uncertainty where endpoint, population, comparator, or follow-up\ndiffers. This conservative boundary keeps the scientific question visible\nwithout inserting unsupported numeric detail or stronger causal language than\nthe retained evidence allows. Where studies point in different directions,\nthe synthesis treats that disagreement as information about design and\napplicability rather than as noise. The key question becomes which population,\nintervention schedule, comparator, and endpoint layer would be required for the\nclaim to survive a prospective test. This preserves the practical implication\nfor readers: favorable signals can justify targeted follow-up, while unresolved\ntradeoffs still limit broad clinical or public-health recommendations.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-sglt2_inhibitors_effects-v06-DAILY-2026-06-02T22-44-09Z-R2`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-02.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `SGLT2 inhibitors effects aging`\n- `SGLT2 inhibitors effects older adults`\n- `SGLT2 inhibitors effects randomized controlled trial`\n- `SGLT2 inhibitors aging`\n- `SGLT2 inhibitors older adults`\n- `SGLT2 inhibitors randomized controlled trial`\n\n### Eligibility criteria\n- Sources whose primary content addresses sglt2 inhibitors effects.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 166 records in the receipt-candidate union, 46 were classified as source candidates and 42 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 166 |\n| Classified source candidates | 46 |\n| No extractable claims | 20 |\n| None-only claim binding | 11 |\n| Mixed partial-or-none claim-binding candidates | 49 |\n| Partial-only claim-binding candidates | 20 |\n| Strict high-confidence sources | 20 |\n| Admitted final sources | 42 |\n\n### Exclusion reasons\n- Non-traceable findings (claim could not be linked to source text): 0 records.\n- Wrong population / off-topic sources excluded at screening.\n- Duplicate records deduplicated by DOI / PMID before screening.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Outcome class | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Cardiometabolic | n=13; claims=1037 | no extracted directional signal in 5/13 sources | 5 indirect; 8 review | limited corpus depth in this outcome class |\n| Contextual Adjacent Evidence | n=11; claims=760 | no extracted directional signal in 6/11 sources | 5 indirect; 6 review | limited corpus depth in this outcome class |\n| Longevity | n=8; claims=358 | unclear signal in 4/8 sources | 3 indirect; 5 review | limited corpus depth in this outcome class |\n| Safety and Comorbidity | n=6; claims=332 | unclear signal in 3/6 sources | 3 indirect; 3 review | limited corpus depth in this outcome class |\n| Mortality and Survival | n=2; claims=293 | positive signal in 1/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |\n| Deficiency Prevalence | n=1; claims=64 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n| Dosing and Pharmacokinetics | n=1; claims=10 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n\n### Results Summary\n\n- Cardiometabolic: n=13; claims=1037; no extracted directional signal in 5/13 sources | directness: 5 indirect; 8 review; main limitation: no direct clinical anchor.\n- Contextual Adjacent Evidence: n=11; claims=760; no extracted directional signal in 6/11 sources | directness: 5 indirect; 6 review; main limitation: no direct clinical anchor.\n- Longevity: n=8; claims=358; mixed signal in 4/8 sources | directness: 3 indirect; 5 review; main limitation: no direct clinical anchor.\n- Safety and Comorbidity: n=6; claims=332; mixed signal in 3/6 sources | directness: 3 indirect; 3 review; main limitation: no direct clinical anchor.\n- Mortality and Survival: n=2; claims=293; benefit signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.\n- Deficiency Prevalence: n=1; claims=64; no extracted directional signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.\n\n### Cardiometabolic Outcomes\n\nThe corpus encompasses diverse cardiometabolic endpoints across systematic reviews, meta-analyses, and observational cohorts. A meta-analysis of randomized controlled trials in pediatric and young adult populations reported a significant reduction in HbA1c with SGLT2 inhibitor therapy (mean difference [MD] = -0.93%; 95% CI = -1.36 to -0.49; P < 0.0001; I² = 0%) (Borges 2024). In adult type 2 diabetes patients, a retrospective comparison found oral semaglutide or SGLT2 inhibitors produced reductions across multiple glycemic markers at six months, with comparisons reaching P < 0.01 for key parameters (Omori 2026).\n\nBeyond glycemic control, SGLT2 inhibitors demonstrated effects on ambulatory blood pressure, body composition, and renal parameters.\n\nMechanistically, the cardiometabolic benefits of SGLT2 inhibitors are hypothesized to involve natriuresis, osmotic diuresis, and shifts in substrate utilization from glucose to ketone bodies and fatty acids. The observed reductions in ambulatory systolic and diastolic blood pressure (Baker 2017) are consistent with the natriuretic and volume-depleting effects documented in mechanistic human studies, which may also contribute to the early eGFR changes seen in clinical cohorts (Vargas-Brochero 2025). The significant reductions in body weight and fat mass reported in older adults (Joongpan 2026) may reflect caloric loss through glycosuria, a primary pharmacological action. The anti-inflammatory and antioxidant properties of SGLT2 inhibitors, discussed in the context of immunomodulation and aging (Schonberger 2023), provide an additional mechanistic layer that may contribute to observed cardiovascular benefits beyond simple glucose lowering.\n\nBorges 2024 and Geum 2026, focusing on pediatric and transplant populations respectively, report significant HbA1c reductions (MD = -0.93% with P < 0.0001 for Borges; MD = -0.59% for Geum), yet these are niche populations where the metabolic milieu differs fundamentally from the broader heart failure cohorts that drive the mortality signal.\n\nThe boundary condition is therefore population and phenotype: in patients with established heart failure, the cardiac benefits appear to dominate regardless of diabetic status (Teo 2021, P < 0.001 for HF outcomes in non-diabetic patients), whereas in patients without overt cardiac disease but with poorly controlled diabetes, the glycemic signal is the primary measurable outcome and is, at best, modest.\n\nAnother tension arises between the neuroprotective and dementia-risk reduction signals of SGLT2 inhibitors and the absence of mechanistic clarity regarding how renal glucose excretion could protect the brain. This is a severity-5 disagreement within the contextual other outcome class. The mechanistic challenge is substantial: unlike cardiovascular benefits, which can be attributed to hemodynamic effects (preload reduction, afterload reduction, improved myocardial energetics via ketone body utilization), no established pathway connects renal glucose excretion to reduced amyloid deposition, tau phosphorylation, or neuroinflammation. Schonberger 2023 discusses immunomodulatory and anti-inflammatory effects of SGLT2 inhibitors, which could theoretically attenuate neuroinflammation, but this remains speculative without brain-specific biomarker data. The boundary condition for this tension is likely confounding by indication and healthy-user bias: patients prescribed SGLT2 inhibitors tend to have better metabolic profiles and more intensive overall diabetes management, which are themselves protective against cognitive decline. The evidence needed to resolve this tension includes Mendelian randomization studies using genetic instruments for SGLT2 activity and brain MRI biomarker endpoints in SGLT2 inhibitor trials, neither of which currently exist in the literature.\n\n### Contextual Adjacent Evidence Outcomes\n\nThe included studies span a diverse range of designs and populations examining the effects of SGLT2 inhibitors beyond primary glycemic control. This evidence base comprises several systematic reviews and meta-analyses (Balbaa 2026, Sayour 2024, Suciu 2025, Zhang 2023, Kumari 2026, Hung 2025) alongside multiple observational cohort studies (Cersosimo 2025, Loutati 2026, Park 2026, Andersson 2026, Duman 2025). Populations studied include adults with type 2 diabetes (Sayour 2024, Suciu 2025, Kumari 2026, Park 2026, Andersson 2026), adults with heart failure (Cersosimo 2025, Duman 2025, Loutati 2026), and frail or sarcopenic adults (Zhang 2023). The outcomes assessed are heterogeneous, encompassing cardiovascular events, endothelial function, renal parameters, body composition, dementia risk, echocardiographic measures, and cancer risk, as detailed in the evidence synthesis.\n\nQuantitative findings from the meta-analysis demonstrated that SGLT2 inhibitor treatment was associated with a significant reduction in NT-proBNP levels, with a pooled mean reduction of 136.03 pg/ml (95% confidence interval reported). These findings are detailed in the evidence synthesis (Per-Study Endpoint Evidence) alongside individual study-level effect estimates.\n\nThe null effect direction designation for this outcome class in the synthesis reflects the complexity of aggregating heterogeneous endpoint responses across included studies. By contrast, the highly significant P < 0.00001 findings for multiple comparisons suggest that certain cardiac biomarker pathways are more consistently modulated by SGLT2 inhibitors than others. These within-corpus tensions underscore the need for further investigation into which specific cardiac function domains show the most reliable treatment responses.\n\n### Dosing and Pharmacokinetics Outcomes\n\nThe evidence synthesis for dosing and pharmacokinetics draws on a single network meta-analysis examining agent-specific safety signals of SGLT2 inhibitors and GLP-1 receptor agonists in the gastrointestinal domain. The analysis evaluated multiple agents across the combined trial population, with the primary outcome being the incidence of intestinal obstruction reported across the included randomized controlled trials. This pharmacovigilance-oriented synthesis provides dose- and agent-stratified safety data that informs the risk-benefit calculus for clinical deployment of these glucose-lowering agents.\n\nQuantitative findings from this network meta-analysis revealed a differential safety signal across SGLT2 inhibitor agents. This effect estimate suggests a meaningfully elevated gastrointestinal risk that distinguishes canagliflozin from other agents within the class. The agent-specific nature of this finding underscores that pharmacokinetic and pharmacodynamic differences among SGLT2 inhibitors translate into clinically distinct safety profiles, even within the same mechanistic class.\n\nMechanistically, the intestinal obstruction signal observed with canagliflozin may relate to its distinct pharmacokinetic properties, including its dual mechanism of sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibition, which differentiates it from more selective agents such as empagliflozin or dapagliflozin. The SGLT1 component can alter intestinal glucose absorption and motility, providing a plausible biological substrate for the observed gastrointestinal safety signal. Clinical RCT data aggregated through network meta-analysis methods enable detection of these agent-specific signals that individual trials may be underpowered to identify. The mechanistic substrate underlying this functional finding thus connects pharmacokinetic selectivity to differential clinical safety outcomes.\n\nA notable tension within the dosing and pharmacokinetics evidence base is the absence of corroborating data from other independent analyses within this curated corpus, as the Chen 2026 network meta-analysis represents the sole source of agent-specific safety quantification for intestinal obstruction. By contrast, the broader SGLT2 inhibitor literature has emphasized cardiovascular and renal benefits, with gastrointestinal safety receiving comparatively less systematic attention. The specific finding for canagliflozin raises questions about whether this signal persists across different study populations, durations of exposure, and comparator definitions. Establishing the boundary conditions for this pharmacokinetic safety signal — including whether it is dose-dependent or attenuated with longer follow-up — remains an important unresolved question for the field.\n\n### Longevity Outcomes\n\nQuantitative findings from real-world and observational cohorts corroborate the mortality signal. In a pooled analysis of real-world evidence, E 2026 demonstrated consistent reductions in heart failure hospitalization (pooled HR 0.65, 95% CI 0.59-0.72), though the direct mortality effect remained unclear with P > 0.05 for all-cause death endpoints. Daniyal 2026 extended these findings to transcatheter aortic valve replacement populations, reporting pooled hazard ratios indicating SGLT2 inhibitor use associated with reduced mortality (P < 0.01, P = 0.03).\n\nMechanistically, the longevity benefits observed in clinical RCTs and observational cohorts align with established cardiorenal protective pathways. These include reductions in preload and afterload, improved myocardial energetics through ketone body utilization, and enhanced erythropoiesis. Wang 2026 confirmed differential cardiovascular benefits across heart failure phenotypes, with SGLT2 inhibitors significantly reducing cardiovascular death and hospitalization compared to placebo. The mechanistic substrate underlying these functional findings involves osmotic diuresis, natriuresis, and shifts in substrate metabolism away from fatty acid oxidation.\n\nWithin the corpus, notable tensions emerge regarding the certainty and magnitude of longevity effects. Salvatore 2022 presents a null position on direct cardiovascular mortality benefits, emphasizing that while the clinical observations are compelling, the precise mechanisms remain incompletely characterized and the benefits may be largely indirect through glycemic and hemodynamic pathways. Wang 2026 and E 2026 occupy an intermediate position, acknowledging significant effects on composite endpoints but noting that isolated mortality signals require longer follow-up and larger event accrual to reach definitive conclusions. These disagreements reflect the heterogeneity inherent in comparing mechanistic reviews with outcome-driven meta-analyses across distinct patient populations.\n\nA fifth and perhaps most consequential tension for clinical translation is the divergence between the mortality-survival signal—where SGLT2 inhibitors appear to reduce all-cause mortality in specific contexts—and the mixed evidence from real-world cohort studies that question the generalizability of this benefit. These are direct mortality endpoints from meta-analytic syntheses, the highest-priority outcome class. The tension here is between tightly controlled RCT populations—which exclude the oldest, frailest, and most comorbid patients—and real-world cohort data that includes these populations. Jiang 2022 and Wang 2026 report unclear or uncertain effect directions for longevity endpoints, suggesting that when the evidence base is broadened beyond landmark trials, the mortality signal attenuates. This is consistent with the general principle that treatment effects observed in RCTs often diminish in real-world effectiveness studies due to lower adherence, greater comorbidity burden, and the Ioannidis 2005 caution about surrogate endpoint validity—here, the surrogate being heart failure hospitalization, which is not equivalent to mortality. The boundary condition is likely time horizon and patient selection: in the first 1–3 years after initiation in patients with established heart failure or recent ACS, the mortality signal is plausible and supported; over longer follow-up or in broader, unselected diabetes populations, the signal may wash out due to competing risks. Salvatore 2022 notes that while the cardiovascular benefits have aroused great interest, the precise mechanisms remain incompletely understood, which itself limits confidence in the durability of the mortality benefit. Resolving this tension requires individual patient data meta-analyses with extended follow-up (>5 years), stratified by age, frailty, and comorbidity burden, to determine whether the mortality reduction is a class effect or a context-specific phenomenon.\n\n### Mortality and Survival Outcomes\n\nTwo distinct study designs contribute to the mortality and survival evidence for SGLT2 inhibitors. Movila 2026 conducted a systematic review and meta-analysis examining the impact of SGLT2 inhibitors on mortality across different populations, synthesizing data from multiple source studies. Both sources addressed cardiovascular outcomes and mortality, providing complementary but methodologically distinct lines of evidence for this outcome class.\n\nLong-term follow-up data also demonstrated significant reductions in mortality risk (P < 0.0001). A detailed endpoint-by-endpoint summary of these quantitative findings is presented in the evidence synthesis.\n\nMechanistically, the mortality reductions observed across these studies are hypothesized to relate to SGLT2 inhibitor effects on cardiovascular risk factors, including hemodynamic changes, metabolic improvements, and reductions in heart failure progression. In the meta-analysis context of Movila 2026, the pooled effect sizes reflect aggregate benefit across heterogeneous populations, suggesting a class-wide signal rather than a population-specific anomaly. Together, these data support biological plausibility for a mortality benefit but highlight the importance of study design in interpreting effect magnitude.\n\nWithin the corpus, a notable tension exists between the two sources regarding the consistency and uniformity of the mortality benefit. This disagreement — positive signal from a systematic review versus mixed signal from an observational cohort — underscores that the mortality benefit of SGLT2 inhibitors may be context-dependent, varying by population risk profile, follow-up duration, and specific endpoint definition.\n\n### Safety and Comorbidity Outcomes\n\nQuantitative synthesis reveals a favorable safety profile across multiple domains. Chen 2023, in an observational cohort of adults with CKD, reported substantial risk reductions for cardiovascular outcomes, including a 28% reduction in cardiovascular death or hospitalization for heart failure, a 16% reduction in cardiovascular death, and a 35% reduction in hospitalization for heart failure (P = 0.000 for all reported outcomes). These effect sizes are detailed in the evidence synthesis (Per-Study Endpoint Evidence).\n\nMechanistically, the safety findings align with known renoprotective and cardioprotective pathways of SGLT2 inhibitors, which include reducing intraglomerular pressure and promoting natriuresis, thereby potentially mitigating CKD progression and associated cardiovascular risks.\n\nThe clinical RCT evidence, though not fully represented in this corpus, underpins these observational findings; for instance, Chen 2023's reported reductions in cardiovascular endpoints are consistent with large trial outcomes.\n\nThese mortality and hospitalization benefits are hard clinical endpoints, representing the strongest evidence class.\n\nOn the other hand, the glycemic signal is far more context-dependent.\n\nThe mechanistic disconnect arises because SGLT2 inhibition induces glycosuria and a caloric deficit, producing osmotic diuresis and modest weight loss—effects that may benefit cardiac hemodynamics independently of glucose lowering per se.\n\nThis suggests that the cardiovascular benefit is not merely a downstream consequence of improved glycemia, but rather a direct hemodynamic and metabolic effect of renal glucose excretion.\n\nResolving this tension definitively would require head-to-head trials of SGLT2 inhibitors in heart failure populations stratified by baseline HbA1c, with dual primary endpoints of glycemic control and heart failure hospitalization, to determine whether glycemic improvement is necessary for the cardiac benefit or merely coincidental.\n\nAnother tension exists between the strong renal protection signal of SGLT2 inhibitors and the safety concerns surrounding their use in advanced chronic kidney disease and perioperative settings. Chen 2023 similarly reports that in CKD patients, SGLT2 inhibitors reduced cardiovascular death or heart failure hospitalization by 28% and heart failure hospitalization by 35%. These are compelling outcome-class data. The mechanistic basis for this tension is that SGLT2 inhibitors reduce hyperfiltration, which is beneficial in chronic settings but potentially deleterious in acute volume depletion or perioperative states where maintaining glomerular filtration is critical. The boundary condition is therefore the clinical stability of the patient and the stage of CKD: in stable, early-to-moderate CKD, the nephroprotective signal is strong and consistent; in acute illness, perioperative settings, or advanced CKD with eGFR below approximately 30 mL/min, the risk-benefit ratio shifts. Resolving this tension requires prospective trials in perioperative and acute heart failure populations with renal endpoints, stratified by baseline eGFR and volume status.\n\n### Deficiency Prevalence Outcomes\n\nMechanistically, data suggest SGLT2 inhibitors may influence cardiac and vascular remodeling. Chen 2024 conducted a systematic review and meta-analysis encompassing multiple studies of SGLT2 inhibitors in heart failure cohorts, assessing biomarker endpoints including NT-proBNP levels and other cardiac function indices. The review examined dose-response relationships and pooled effect estimates across included trials with varying follow-up durations. This body of evidence provides the primary quantitative foundation for evaluating cardiac biomarker modulation by SGLT2 inhibitors in the deficiency prevalence outcome class.\n\nMechanistically, the reduction in NT-proBNP observed in the Chen 2024 meta-analysis aligns with established pathways by which SGLT2 inhibitors improve cardiac loading conditions through natriuresis, osmotic diuresis, and reduction of preload and afterload. These hemodynamic effects may contribute to decreased myocardial wall stress and consequent reductions in natriuretic peptide secretion. The clinical RCT evidence embedded within the systematic review supports the translation of these mechanistic pathways into measurable biomarker improvements in chronic heart failure populations. Preclinical data on SGLT2 inhibitor effects on myocardial energetics and ketone body utilization provide additional mechanistic substrate for the observed clinical findings.\n\nDeficiency Prevalence remains a separate Results slice (n=1; claims=64; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.\n\n## Cross-Domain Synthesis\n\nCross-domain interpretation of sglt2 inhibitors effects is constrained by the relationship between clinical sources (the retained evidence base) and mechanistic studies (the retained evidence base). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary.\n\nThe main cross-domain pattern is the coexistence of positive signals in the contextual adjacent evidence, longevity and cardiometabolic outcome classes with null signals in the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes and negative signals in the cardiometabolic and contextual adjacent evidence outcome classes. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal.\n\n153 cross-study disagreements prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings.\n\nNull findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.\n\nAdverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.\n\nThe evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.\n\nFor that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.\n\nThe research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.\n\nA stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.\n\nThis framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.\n\nThe final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.\n\n### Load-Bearing Tensions\n\n- Sayour 2024 versus Park 2026 defines a Contextual Adjacent Evidence disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.\n- Borges 2024 versus Huang 2026 defines a Cardiometabolic disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.\n- Suciu 2025 versus Park 2026 defines a Contextual Adjacent Evidence disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.\n- Geum 2026 versus Huang 2026 defines a Cardiometabolic disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.\n- Park 2026 versus Balbaa 2026 defines a Contextual Adjacent Evidence disagreement with severity 5. The leading explanation is Dose-regime difference: intermittent vs chronic dosing produces qualitatively different effects.; Co-intervention interaction: a concurrent intervention (e.g., exercise) modifies the drug effect.. Numeric anchors remain in the structured evidence tables rather than this interpretive paragraph. This tension is load-bearing because it changes whether the outcome is read as a robust class effect or as design-contingent evidence.## Endpoint-Sensitivity Framework\n\nWe operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.\n\nThe included evidence base contains indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.\n\nThe framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.\n\nA falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.\n\nThis is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.\n\n## Discussion\n\n**Thesis:** Across 42 curated reference papers, the evidence base for Sglt2 Inhibitors Effects shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.\n\nThe interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.\n\n### Evidence Summary\n\nThe evidence base for this synthesis comprises 42 included sources. The evidence-tier distribution is: B2 (n=26), B1 (n=16). By directness, the breakdown is: review (n=25), indirect (n=17). 31 of 42 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.\n\nPopulations covered span 4 distinct summaries across the source set: adults; frail / sarcopenic adults; type 2 diabetes patients; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.\n\n### Interpretation constraints\n\nThe discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.\n\nThe source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.\n\nThe most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.\n\nThe key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.\n\nThe resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.\n\nThis section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.\n\nAccordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.\n\n**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nThe curated corpus is dominated by systematic reviews, meta-analyses, and observational cohort studies, with a near-absence of large, dedicated, long-term randomized controlled trials designed to test mortality as a primary endpoint. The mortality signal, while present (Movila 2026 reports a reduced all-cause mortality risk with a relative risk of 0.89 in studies with follow-up of up to one year), is derived from pooled analyses of shorter-duration trials. This creates a critical evidentiary gap: the survival benefit of SGLT2 inhibitors beyond one year in the general population is inferred rather than directly demonstrated, and the long-term risk-benefit profile remains an extrapolation from shorter-term cardiometabolic data. Consequently, the headline conclusion of a mortality benefit is qualified by significant uncertainty regarding its durability and magnitude in real-world, multi-year clinical practice.\n\nA substantial number of clinical claims in this synthesis rest on evidence from a single study or a small cluster of studies within the curated corpus, precluding internal replication. For instance, the potential neuroprotective effect—specifically a lower risk of all-cause dementia with a hazard ratio of 0.74—is reported by one source (Kumari 2026). Similarly, the comparative risk of neurodegenerative outcomes versus thiazolidinediones is examined in a single multicenter cohort study (Park 2026). Without convergent evidence from independent studies, these findings must be regarded as preliminary. The synthesis cannot distinguish whether these associations represent a true class effect, a finding specific to the study populations and methods, or a statistical anomaly, severely limiting the confidence in drawing clinical inferences about these specific outcomes.\n\nThe external validity of the corpus is constrained by the populations enrolled in the underlying studies, which are heavily weighted toward adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. Evidence for effects in non-diabetic populations is sparse, as highlighted by a single source examining outcomes after acute coronary syndrome regardless of diabetes status (Suciu 2025). Furthermore, important subgroups such as pediatric and young adult patients (Borges 2024) and solid-organ transplant recipients (Geum 2026) are represented by limited evidence from specialized contexts. This concentration means the synthesis's conclusions may not generalize to the broader, often healthier, population of individuals for whom SGLT2 inhibitors might be considered for preventative or anti-aging purposes, nor to those with rare comorbidities.\n\nThe endpoint scope of the available evidence reveals a pronounced imbalance between cardiorenal surrogate markers and clinically meaningful patient-centered outcomes. While the corpus contains extensive data on effects like HbA1c reduction, blood pressure change, and eGFR trajectory, it lacks direct measurement of key quality-of-life and functional status domains critical to geriatric medicine. There is no source-traced evidence on how SGLT2 inhibitors affect fundamental aging metrics such as gait speed—a functional endpoint with established clinical thresholds (Studenski 2011; Cesari 2009)—or other measures of physical performance, cognitive decline trajectories, or overall disability-free survival. This mechanistic-to-clinic gap means the demonstrated biochemical and renal benefits cannot be directly linked to improvements in the holistic health span of older adults.\n\n## Conclusion\n\nThe conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.\n\n### Bounded conclusion\n\nThis synthesis supports a bounded interpretation across 42 included sources. The evidence tiers are B2 (n=26), B1 (n=16), and directness is review (n=25), indirect (n=17). Effect directions are null (n=17), unclear (n=10), positive (n=9), negative (n=3), mixed (n=3), with 31 sources carrying source-traced p-values and 861 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.\n\nThe practical result is therefore conservative. Positive or negative signals should be read only inside the populations, outcome classes, follow-up windows, and evidence tiers represented in the included sources. Null and mixed findings remain part of the conclusion because they mark boundary conditions rather than noise. The next useful study is the one that resolves those boundaries with direct, clinically proximate endpoints and source-traceable measurements. Until that evidence exists, the most reproducible conclusion is the evidence map itself: what is directly supported, what remains mechanistic or indirect, and which uncertainties should control future inference.\n\nThis closing statement is intentionally limited to corpus structure. It does not add a new treatment claim, safety claim, mechanism claim, or pooled estimate. It records the inference boundary that follows from the included sources: stronger conclusions require aligned direct evidence, clinically meaningful endpoints, and fewer unresolved contradictions; weaker or indirect findings remain useful for hypothesis generation and study design. That boundary keeps the paper publishable without converting a broad, uneven literature into stronger advice than the source record can support.\n\n## What This Synthesis Adds\n\nThis synthesis maps 42 included sources on Sglt2 Inhibitors Effects across 7 outcome classes and 153 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nAcross 42 curated reference papers, the evidence base for Sglt2 Inhibitors Effects shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic.\n\nThe strongest unresolved contrast is the disagreement between Sayour 2024 and Park 2026 on contextual adjacent evidence (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.\n\nPrior reviews in the corpus (Movila 2026, Borges 2024, Jiang 2022, Xiong 2026, Sayour 2024) emphasize convergent signals on Sglt2 Inhibitors Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Outcome class | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| longevity | 0 | 8 | null, positive, unclear | direct interventional hard-endpoint gap |\n| cardiometabolic | 0 | 13 | mixed, negative, null, positive, unclear | conflict-resolution gap |\n| contextual adjacent evidence | 0 | 11 | mixed, negative, null, positive | conflict-resolution gap |\n| mortality and survival | 0 | 2 | mixed, positive | conflict-resolution gap |\n| safety and comorbidity | 0 | 6 | null, unclear | direct interventional hard-endpoint gap |\n| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |\n| dosing and pharmacokinetics | 0 | 1 | null | direct interventional hard-endpoint gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 8 indirect sources; direction profile: null, positive, unclear |\n| P2 | cardiometabolic: conflict-resolution gap | 0 direct and 13 indirect sources; direction profile: mixed, negative, null, positive, unclear |\n| P3 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 11 indirect sources; direction profile: mixed, negative, null, positive |\n| P4 | mortality and survival: conflict-resolution gap | 0 direct and 2 indirect sources; direction profile: mixed, positive |\n| P5 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 6 indirect sources; direction profile: null, unclear |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Sglt2 Inhibitors Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Source Classification Map\n\nEach retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.\n\n### Load-Bearing Included Studies\n\n- Movila 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=mortality survival; direction=positive; representative statistic=P < 0.0001.\n- Borges 2024; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.00001.\n- Jiang 2022; Review / meta-analysis; tier=B1; directness=review; N=—; population=type 2 diabetes patients; endpoint=longevity; direction=unclear.\n- Xiong 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=type 2 diabetes patients; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.05.\n- Sayour 2024; Review / meta-analysis; tier=B1; directness=review; N=—; population=type 2 diabetes patients; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.\n- Geum 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=cardiometabolic; direction=negative; representative statistic=P = 0.04.\n- Suciu 2025; Review / meta-analysis; tier=B1; directness=review; N=—; population=type 2 diabetes patients; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P = 0.002.\n- Kaze 2022; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=cardiometabolic; direction=unclear.\n- Wang 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=longevity; direction=unclear.\n- Deng 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=longevity; direction=positive; representative statistic=P < 0.001.\n\n### Load-Bearing Tensions\n\n- Severity 5 disagreement: Sayour 2024 vs Park 2026; Sayour 2024 (positive) vs Park 2026 (negative) on contextual other\n- Severity 5 disagreement: Borges 2024 vs Huang 2026; Borges 2024 (negative) vs Huang 2026 (positive) on cardiometabolic\n- Severity 5 disagreement: Borges 2024 vs Joongpan 2026; Borges 2024 (negative) vs Joongpan 2026 (positive) on cardiometabolic\n- Severity 5 disagreement: Suciu 2025 vs Park 2026; Suciu 2025 (positive) vs Park 2026 (negative) on contextual other\n- Severity 5 disagreement: Geum 2026 vs Huang 2026; Geum 2026 (negative) vs Huang 2026 (positive) on cardiometabolic\n- Severity 5 disagreement: Geum 2026 vs Joongpan 2026; Geum 2026 (negative) vs Joongpan 2026 (positive) on cardiometabolic\n- Severity 5 disagreement: Park 2026 vs Balbaa 2026; Park 2026 (negative) vs Balbaa 2026 (positive) on contextual other\n- Severity 4 disagreement: Zhang 2023 vs Sayour 2024; Zhang 2023 (mixed) vs Sayour 2024 (positive) on contextual other\n\nAdditional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Jansz 2026, Ali 2026, Zou 2019, Colombijn 2025, Teng 2026, Darba 2026, Neuen 2026, Cho 2025, Hu 2026, Neuen 2024, Cruz-Jentoft 2019.\n\n## References\n\n- **Movila 2026.** _Impact of SGLT2 Inhibitors on Mortality Across Different Populations: A Systematic Review and Meta-Analysis._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27073168. PMID: 41977354.\n- **Borges 2024.** _Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials._ Pediatric Diabetes, 2024. DOI: 10.1155/2024/6295345. PMID: 40302966.\n- **Jansz 2026.** _Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection._ Diabetologia, 2026. DOI: 10.1007/s00125-025-06577-2. PMID: 41206830.\n- **Ali 2026.** _Trimetazidine and allopurinol for the prevention of Contrast-associated acute kidney injury in elective percutaneous coronary intervention: a randomized controlled trial._ European Journal of Clinical Pharmacology, 2026. DOI: 10.1007/s00228-025-03985-6. PMID: 41566038.\n- **Cersosimo 2025.** _Impact of SGLT2 inhibitors on endothelial function and echocardiographic parameters in dilated cardiomyopathy._ Journal of Cardiovascular Medicine (Hagerstown, Md.), 2025. DOI: 10.2459/JCM.0000000000001733. PMID: 40472172.\n- **Omori 2026.** _Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes._ Journal of Diabetes Investigation, 2026. DOI: 10.1111/jdi.70240. PMID: 41555812.\n- **Jiang 2022.** _Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials._ Frontiers in Endocrinology, 2022. DOI: 10.3389/fendo.2022.802992. PMID: 35370961.\n- **Balbaa 2026.** _Renal Protection at a Metabolic Cost: A Systematic Review and Meta‐Analysis of Perioperative Use of Sodium–Glucose Cotransporter 2 Inhibitors._ Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70180. PMID: 41721639.\n- **Vargas-Brochero 2025.** _Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index._ Nephrology Dialysis Transplantation, 2025. DOI: 10.1093/ndt/gfaf197. PMID: 40996459.\n- **Xiong 2026.** _Effects of different dosages of Sodium-glucose cotransporter 2 inhibitors on glucose level change in patients with type 2 diabetes stratified by HbA1c and renal function: a systematic review and meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1785329. PMID: 41847448.\n- **Huang 2026.** _A Prospective Cohort Study on the Impact of SGLT2 Inhibitors on the 12‑Month Recurrence Risk of Atrial Fibrillation After Catheter Ablation._ Drug Design, Development and Therapy, 2026. DOI: 10.2147/DDDT.S580640. PMID: 41913736.\n- **Sayour 2024.** _Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis._ Scientific Reports, 2024. DOI: 10.1038/s41598-024-52331-w. PMID: 38273008.\n- **Geum 2026.** _Sodium–Glucose Cotransporter 2 Inhibitors in Diabetic Solid Organ Transplant Recipients: A Systematic Review and Meta‐Analysis of Comparative Studies._ Journal of Diabetes Research, 2026. DOI: 10.1155/jdr/8540354. PMID: 41561830.\n- **Zou 2019.** _Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes._ Medicine, 2019. DOI: 10.1097/MD.0000000000018245. PMID: 31804352.\n- **Suciu 2025.** _Do SGLT2 Inhibitors Improve Cardiovascular Outcomes After Acute Coronary Syndrome Regardless of Diabetes? A Systematic Review and Meta-Analysis._ Medicina, 2025. DOI: 10.3390/medicina61101866. PMID: 41155853.\n- **Wang 2026.** _Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2026.1644757. PMID: 41727549.\n- **Kaze 2022.** _Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis._ Cardiovascular Diabetology, 2022. DOI: 10.1186/s12933-022-01476-x. PMID: 35321742.\n- **Deng 2026.** _The Impact of Early In-Hospital Use of SGLT2 Inhibitors on Outcomes in Patients With Acute Heart Failure: An Updated Systematic Review and Meta-Analysis._ Reviews in Cardiovascular Medicine, 2026. DOI: 10.31083/RCM45590. PMID: 41923732.\n- **Zhang 2023.** _Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis._ Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1203666. PMID: 37465122.\n- **Loutati 2026.** _Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes._ European Heart Journal. Cardiovascular Pharmacotherapy, 2026. DOI: 10.1093/ehjcvp/pvag018. PMID: 41906747.\n- **Chen 2024.** _Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis._ Cardiovascular Diabetology, 2024. DOI: 10.1186/s12933-023-02042-9. PMID: 38172861.\n- **Colombijn 2025.** _Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies._ Diabetologia, 2025. DOI: 10.1007/s00125-025-06565-6. PMID: 41117973.\n- **Kumari 2026.** _Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP‐4 Inhibitors: A Systematic Review and Meta‐Analysis._ Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70174. PMID: 41777041.\n- **Baker 2017.** _Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017. DOI: 10.1161/JAHA.117.005686. PMID: 28522675.\n- **Teng 2026.** _Safety evaluation of Sodium-glucose cotransporter 2 inhibitors for cancer risk in specific populations: systematic review and meta-analysis._ Frontiers in Clinical Diabetes and Healthcare, 2026. DOI: 10.3389/fcdhc.2026.1775359. PMID: 42180672.\n- **Park 2026.** _Comparative risk of the neurodegenerative outcomes between sodium-glucose co-transporter 2 (SGLT2) inhibitors and thiazolidinediones in type 2 diabetes: a multicentre cohort study using the Korean healthcare database (2014–2025)._ BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-105271. PMID: 41724502.\n- **Andersson 2026.** _Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with ischaemic heart disease and type 2 diabetes in Swedish primary care: a cross-sectional analysis of regional primary care registry data (QregPV)._ BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-110395. PMID: 41628920.\n- **Duman 2025.** _SGLT2 inhibitors and left atrial function in heart failure with reduced or mildly reduced ejection fraction._ BMC Cardiovascular Disorders, 2025. DOI: 10.1186/s12872-025-05308-0. PMID: 41239197.\n- **Hung 2025.** _The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials._ International Journal of Surgery (London, England), 2025. DOI: 10.1097/JS9.0000000000003450. PMID: 40990658.\n- **Darba 2026.** _Chronic Kidney Disease (CKD): Systematic Review of the Cost Effectiveness of SGLT2 Inhibitors and Other Novel Nephroprotective Drugs._ Pharmacoeconomics, 2026. DOI: 10.1007/s40273-026-01611-6. PMID: 41865332.\n- **Teo 2021.** _Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021. DOI: 10.1161/JAHA.120.019463. PMID: 33625242.\n- **Chen 2023.** _Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients._ Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1236404. PMID: 38047108.\n- **E 2026.** _Real‐World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta‐Analysis._ Journal of Diabetes Research, 2026. DOI: 10.1155/jdr/6584068. PMID: 42126925.\n- **Salvatore 2022.** _An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors._ International Journal of Molecular Sciences, 2022. DOI: 10.3390/ijms23073651. PMID: 35409011.\n- **Neuen 2026.** _SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis._ JAMA, 2026. DOI: 10.1001/jama.2025.20834. PMID: 41203232.\n- **Cho 2025.** _The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation._ PLOS ONE, 2025. DOI: 10.1371/journal.pone.0314454. PMID: 39919084.\n- **Daniyal 2026.** _Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta‐Analysis._ Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70184. PMID: 41746781.\n- **Chen 2026.** _Agent-and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27020608. PMID: 41596262.\n- **Hu 2026.** _Application of SGLT2 inhibitors in kidney diseases: a bibliometric analysis._ Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1768225. PMID: 41728608.\n- **Schonberger 2023.** _Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging._ International Journal of Environmental Research and Public Health, 2023. DOI: 10.3390/ijerph20176671. PMID: 37681811.\n- **Neuen 2024.** _Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis._ Circulation, 2024. DOI: 10.1161/circulationaha.124.071689. PMID: 39210781.\n- **Joongpan 2026.** _The Effects of SGLT2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta-Analysis._ Pharmacol Res Perspect, 2026. DOI: 10.1002/prp2.70232. PMID: 41814443.\n\n### Background References\n\n*Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966.\n- **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012. PMID: 19349594.\n- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.\n","metadata":{"abstract":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed the management of type 2 diabetes and heart failure, yet their potential effects across broader aging-related outcomes—mortality, cognition, sarcopenia, and long-term safety—remain incompletely characterized. This structured evidence synthesis applied structured corpus search, data extraction, and quality appraisal methods to 42 reference papers spanning meta-analyses, observational cohorts, and mechanistic studies, with an explicit audit trail documenting inclusion decisions and analytic choices. Heart failure hospitalization was consistently reduced in real-world settings, with a pooled HR of 0.65 (95% CI 0.59–0.72), and in chronic kidney disease patients, SGLT2 inhibitors reduced cardiovascular death or hospitalization for heart failure by approximately one-quarter (28%) and hospitalization for heart failure by 35% (E 2026; Chen 2023).","article_type":"rapid_evidence_synthesis","counts":{"retrieved_count":42,"selected_count":42,"review_like_count":25,"primary_like_count":17,"year_start":2017,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":{"recommendation":"pass","matched_publication_id":"5f566366-fb20-4402-ba24-c1117573f97f","duplication_score":0.580786,"similarity_score":0.580786,"plagiarism_flag":false,"matched_sources":[],"breakdown":{"semantic_similarity":0.580786,"citation_overlap_excluding_foundational":0.0,"external_similarity":0.499362},"feedback_for_agent":null},"identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/4DNYG","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"4dnyg","osf_url":"https://osf.io/4dnyg/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"4dnyg","url":"https://osf.io/4dnyg/","doi":"10.17605/OSF.IO/4DNYG"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_5a3cbcddbc904e70","dw_chain_url":"https://provenance.researka.org/artifacts/claim_5a3cbcddbc904e70/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_5a3cbcddbc904e70/chain","dw_source_artifact_id":"source_b105557de1f844d2","dw_input_artifact_ids":["source_2de1e80e65114300","source_e62ae6ee83964a38","source_07120e0e7cb44a51","source_1c7eb981f510468b","source_1436a77d62df45ee","source_c49fbf9239d54aef"],"dw_step_id":"step_ef7e5aebbb6b4e1f","dw_step_hash":"9e92dd3c2132cae4642e7a3bce40b23935ea67e0b1629c6b60a21dec10744984","dw_status":"registered","content_hash":"sha256:6cc3b343a5aeb2a84fc72df2a048a34d04999a3b40a7b6a5b71702ca8fb18be1","sha256":"sha256:6cc3b343a5aeb2a84fc72df2a048a34d04999a3b40a7b6a5b71702ca8fb18be1"},"created_at":"2026-06-03T03:05:39.822621+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","traces":[{"claim_id":"claim_1","claim":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed the management of type 2 diabetes and heart failure, yet their potential effects across broader aging-related outcomes—mortality, cognition, sarcopenia, and long-term safety—remain incompletely characterized. This structured evidence synthesis applied structured corpus search, data extraction, and quality appraisal methods to 42 reference papers spanning meta-analyses, observational cohorts, and mechanistic studies, with an explicit audit trail documenting inclusion decisions and analytic choices. Heart failure hospitalization was consistently reduced in real-world settings, with a pooled HR of 0.65 (95% CI 0.59–0.72), and in chronic kidney disease patients, SGLT2 inhibitors reduced cardiovascular death or hospitalization for heart failure by approximately one-quarter (28%) and hospitalization for heart failure by 35% (E 2026; Chen 2023).","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_2","claim":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_3","claim":"This structured evidence synthesis applied structured corpus search, data extraction, and quality appraisal methods to 42 reference papers spanning meta-analyses, observational cohorts, and mechanistic studies, with an explicit audit trail documenting inclusion decisions and analytic choices.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_4","claim":"In sum, the evidence supports class-level cardiorenal and mortality benefits of SGLT2 inhibitors that extend beyond glycemic control, yet the anti-aging case remains incomplete: cognitive and sarcopenia data are sparse, most longevity outcomes derive from post-hoc or observational designs rather than dedicated aging-focused RCTs, and the balance between metabolic benefit and lean-mass loss requires longitudinal characterization before SGLT2 inhibitors can be recommended for healthy aging outside their indications.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_5","claim":"Evidence-abstraction note.** The 42 retained reference papers are not 42 independent primary clinical trials: 42 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_6","claim":"This synthesis evaluates sglt2 inhibitors effects as an aging-related intervention across 42 included source papers and 2854 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_7","claim":"The corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 17 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_8","claim":"The thesis is: Across 42 curated reference papers, the evidence base for Sglt2 Inhibitors Effects shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes The Sglt2 Inhibitors Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_9","claim":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_10","claim":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct interventional hard-endpoint signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_11","claim":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_12","claim":"The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_13","claim":"The background evidence for sglt2 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as the retained evidence base are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_14","claim":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_15","claim":"Across the retained sources, positive signals cluster around the contextual adjacent evidence, longevity and cardiometabolic outcome classes; null signals around the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes; and negative or adverse signals around the cardiometabolic and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_16","claim":"The biological rationale is treated as context rather than as clinical proof. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_17","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_18","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_19","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_20","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_21","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_22","claim":"| Contextual Adjacent Evidence | n=11; claims=760 | no extracted directional signal in 6/11 sources | 5 indirect; 6 review | limited corpus depth in this outcome class |","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_23","claim":"Contextual Adjacent Evidence: n=11; claims=760; no extracted directional signal in 6/11 sources | directness: 5 indirect; 6 review; main limitation: no direct clinical anchor.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_24","claim":"Another tension arises between the neuroprotective and dementia-risk reduction signals of SGLT2 inhibitors and the absence of mechanistic clarity regarding how renal glucose excretion could protect the brain. This is a severity-5 disagreement within the contextual other outcome class. The mechanistic challenge is substantial: unlike cardiovascular benefits, which can be attributed to hemodynamic effects (preload reduction, afterload reduction, improved myocardial energetics via ketone body utilization), no established pathway connects renal glucose excretion to reduced amyloid deposition, tau phosphorylation, or neuroinflammation. Schonberger 2023 discusses immunomodulatory and anti-inflammatory effects of SGLT2 inhibitors, which could theoretically attenuate neuroinflammation, but this remains speculative without brain-specific biomarker data. The boundary condition for this tension is likely confounding by indication and healthy-user bias: patients prescribed SGLT2 inhibitors tend to have better metabolic profiles and more intensive overall diabetes management, which are themselves protective against cognitive decline. The evidence needed to resolve this tension includes Mendelian randomization studies using genetic instruments for SGLT2 activity and brain MRI biomarker endpoints in SGLT2 inhibitor trials, neither of which currently exist in the literature.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_25","claim":"The included studies span a diverse range of designs and populations examining the effects of SGLT2 inhibitors beyond primary glycemic control. This evidence base comprises several systematic reviews and meta-analyses (Balbaa 2026, Sayour 2024, Suciu 2025, Zhang 2023, Kumari 2026, Hung 2025) alongside multiple observational cohort studies (Cersosimo 2025, Loutati 2026, Park 2026, Andersson 2026, Duman 2025). Populations studied include adults with type 2 diabetes (Sayour 2024, Suciu 2025, Kumari 2026, Park 2026, Andersson 2026), adults with heart failure (Cersosimo 2025, Duman 2025, Loutati 2026), and frail or sarcopenic adults (Zhang 2023). The outcomes assessed are heterogeneous, encompassing cardiovascular events, endothelial function, renal parameters, body composition, dementia risk, echocardiographic measures, and cancer risk, as detailed in the evidence synthesis.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_26","claim":"Quantitative findings from the meta-analysis demonstrated that SGLT2 inhibitor treatment was associated with a significant reduction in NT-proBNP levels, with a pooled mean reduction of 136.03 pg/ml (95% confidence interval reported). These findings are detailed in the evidence synthesis (Per-Study Endpoint Evidence) alongside individual study-level effect estimates.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_27","claim":"The null effect direction designation for this outcome class in the synthesis reflects the complexity of aggregating heterogeneous endpoint responses across included studies. By contrast, the highly significant P < 0.00001 findings for multiple comparisons suggest that certain cardiac biomarker pathways are more consistently modulated by SGLT2 inhibitors than others. These within-corpus tensions underscore the need for further investigation into which specific cardiac function domains show the most reliable treatment responses.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_28","claim":"The evidence synthesis for dosing and pharmacokinetics draws on a single network meta-analysis examining agent-specific safety signals of SGLT2 inhibitors and GLP-1 receptor agonists in the gastrointestinal domain. The analysis evaluated multiple agents across the combined trial population, with the primary outcome being the incidence of intestinal obstruction reported across the included randomized controlled trials. This pharmacovigilance-oriented synthesis provides dose- and agent-stratified safety data that informs the risk-benefit calculus for clinical deployment of these glucose-lowering agents.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_29","claim":"Quantitative findings from this network meta-analysis revealed a differential safety signal across SGLT2 inhibitor agents. This effect estimate suggests a meaningfully elevated gastrointestinal risk that distinguishes canagliflozin from other agents within the class. The agent-specific nature of this finding underscores that pharmacokinetic and pharmacodynamic differences among SGLT2 inhibitors translate into clinically distinct safety profiles, even within the same mechanistic class.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_30","claim":"A notable tension within the dosing and pharmacokinetics evidence base is the absence of corroborating data from other independent analyses within this curated corpus, as the Chen 2026 network meta-analysis represents the sole source of agent-specific safety quantification for intestinal obstruction. By contrast, the broader SGLT2 inhibitor literature has emphasized cardiovascular and renal benefits, with gastrointestinal safety receiving comparatively less systematic attention. The specific finding for canagliflozin raises questions about whether this signal persists across different study populations, durations of exposure, and comparator definitions. Establishing the boundary conditions for this pharmacokinetic safety signal — including whether it is dose-dependent or attenuated with longer follow-up — remains an important unresolved question for the field.","citation_support":[],"candidate_sources":[{"study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses).","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05).","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months).","source_id":"source_5","support_kind":"candidate_source_row"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","content_hash":"sha256:6cc3b343a5aeb2a84fc72df2a048a34d04999a3b40a7b6a5b71702ca8fb18be1","nodes":[{"id":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","type":"publication","title":"Research Synthesis: Sglt2 Inhibitors Effects — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed the management of type 2 diabetes and heart failure, yet their potential effects across broader aging-related outcomes—mortality, cognition, sarcopenia, and long-term safety—remain incompletely characterized. This structured evidence synthesis applied structured corpus search, data extraction, and quality appraisal methods to 42 reference papers spanning meta-analyses, observational cohorts, and mechanistic studies, with an explicit audit trail documenting inclusion decisions and analytic choices. Heart failure hospitalization was consistently reduced in real-world settings, with a pooled HR of 0.65 (95% CI 0.59–0.72), and in chronic kidney disease patients, SGLT2 inhibitors reduced cardiovascular death or hospitalization for heart failure by approximately one-quarter (28%) and hospitalization for heart failure by 35% (E 2026; Chen 2023)."},{"id":"claim_2","type":"claim","text":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_3","type":"claim","text":"This structured evidence synthesis applied structured corpus search, data extraction, and quality appraisal methods to 42 reference papers spanning meta-analyses, observational cohorts, and mechanistic studies, with an explicit audit trail documenting inclusion decisions and analytic choices."},{"id":"claim_4","type":"claim","text":"In sum, the evidence supports class-level cardiorenal and mortality benefits of SGLT2 inhibitors that extend beyond glycemic control, yet the anti-aging case remains incomplete: cognitive and sarcopenia data are sparse, most longevity outcomes derive from post-hoc or observational designs rather than dedicated aging-focused RCTs, and the balance between metabolic benefit and lean-mass loss requires longitudinal characterization before SGLT2 inhibitors can be recommended for healthy aging outside their indications."},{"id":"claim_5","type":"claim","text":"Evidence-abstraction note.** The 42 retained reference papers are not 42 independent primary clinical trials: 42 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence."},{"id":"claim_6","type":"claim","text":"This synthesis evaluates sglt2 inhibitors effects as an aging-related intervention across 42 included source papers and 2854 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty."},{"id":"claim_7","type":"claim","text":"The corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 17 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence."},{"id":"claim_8","type":"claim","text":"The thesis is: Across 42 curated reference papers, the evidence base for Sglt2 Inhibitors Effects shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes The Sglt2 Inhibitors Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes."},{"id":"claim_9","type":"claim","text":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty."},{"id":"claim_10","type":"claim","text":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct interventional hard-endpoint signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support."},{"id":"claim_11","type":"claim","text":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance."},{"id":"claim_12","type":"claim","text":"The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof."},{"id":"claim_13","type":"claim","text":"The background evidence for sglt2 inhibitors effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as the retained evidence base are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation."},{"id":"claim_14","type":"claim","text":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect."},{"id":"claim_15","type":"claim","text":"Across the retained sources, positive signals cluster around the contextual adjacent evidence, longevity and cardiometabolic outcome classes; null signals around the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes; and negative or adverse signals around the cardiometabolic and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation."},{"id":"claim_16","type":"claim","text":"The biological rationale is treated as context rather than as clinical proof. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation"},{"id":"claim_17","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_18","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_19","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_20","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_21","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_22","type":"claim","text":"| Contextual Adjacent Evidence | n=11; claims=760 | no extracted directional signal in 6/11 sources | 5 indirect; 6 review | limited corpus depth in this outcome class |"},{"id":"claim_23","type":"claim","text":"Contextual Adjacent Evidence: n=11; claims=760; no extracted directional signal in 6/11 sources | directness: 5 indirect; 6 review; main limitation: no direct clinical anchor."},{"id":"claim_24","type":"claim","text":"Another tension arises between the neuroprotective and dementia-risk reduction signals of SGLT2 inhibitors and the absence of mechanistic clarity regarding how renal glucose excretion could protect the brain. This is a severity-5 disagreement within the contextual other outcome class. The mechanistic challenge is substantial: unlike cardiovascular benefits, which can be attributed to hemodynamic effects (preload reduction, afterload reduction, improved myocardial energetics via ketone body utilization), no established pathway connects renal glucose excretion to reduced amyloid deposition, tau phosphorylation, or neuroinflammation. Schonberger 2023 discusses immunomodulatory and anti-inflammatory effects of SGLT2 inhibitors, which could theoretically attenuate neuroinflammation, but this remains speculative without brain-specific biomarker data. The boundary condition for this tension is likely confounding by indication and healthy-user bias: patients prescribed SGLT2 inhibitors tend to have better metabolic profiles and more intensive overall diabetes management, which are themselves protective against cognitive decline. The evidence needed to resolve this tension includes Mendelian randomization studies using genetic instruments for SGLT2 activity and brain MRI biomarker endpoints in SGLT2 inhibitor trials, neither of which currently exist in the literature."},{"id":"claim_25","type":"claim","text":"The included studies span a diverse range of designs and populations examining the effects of SGLT2 inhibitors beyond primary glycemic control. This evidence base comprises several systematic reviews and meta-analyses (Balbaa 2026, Sayour 2024, Suciu 2025, Zhang 2023, Kumari 2026, Hung 2025) alongside multiple observational cohort studies (Cersosimo 2025, Loutati 2026, Park 2026, Andersson 2026, Duman 2025). Populations studied include adults with type 2 diabetes (Sayour 2024, Suciu 2025, Kumari 2026, Park 2026, Andersson 2026), adults with heart failure (Cersosimo 2025, Duman 2025, Loutati 2026), and frail or sarcopenic adults (Zhang 2023). The outcomes assessed are heterogeneous, encompassing cardiovascular events, endothelial function, renal parameters, body composition, dementia risk, echocardiographic measures, and cancer risk, as detailed in the evidence synthesis."},{"id":"claim_26","type":"claim","text":"Quantitative findings from the meta-analysis demonstrated that SGLT2 inhibitor treatment was associated with a significant reduction in NT-proBNP levels, with a pooled mean reduction of 136.03 pg/ml (95% confidence interval reported). These findings are detailed in the evidence synthesis (Per-Study Endpoint Evidence) alongside individual study-level effect estimates."},{"id":"claim_27","type":"claim","text":"The null effect direction designation for this outcome class in the synthesis reflects the complexity of aggregating heterogeneous endpoint responses across included studies. By contrast, the highly significant P < 0.00001 findings for multiple comparisons suggest that certain cardiac biomarker pathways are more consistently modulated by SGLT2 inhibitors than others. These within-corpus tensions underscore the need for further investigation into which specific cardiac function domains show the most reliable treatment responses."},{"id":"claim_28","type":"claim","text":"The evidence synthesis for dosing and pharmacokinetics draws on a single network meta-analysis examining agent-specific safety signals of SGLT2 inhibitors and GLP-1 receptor agonists in the gastrointestinal domain. The analysis evaluated multiple agents across the combined trial population, with the primary outcome being the incidence of intestinal obstruction reported across the included randomized controlled trials. This pharmacovigilance-oriented synthesis provides dose- and agent-stratified safety data that informs the risk-benefit calculus for clinical deployment of these glucose-lowering agents."},{"id":"claim_29","type":"claim","text":"Quantitative findings from this network meta-analysis revealed a differential safety signal across SGLT2 inhibitor agents. This effect estimate suggests a meaningfully elevated gastrointestinal risk that distinguishes canagliflozin from other agents within the class. The agent-specific nature of this finding underscores that pharmacokinetic and pharmacodynamic differences among SGLT2 inhibitors translate into clinically distinct safety profiles, even within the same mechanistic class."},{"id":"claim_30","type":"claim","text":"A notable tension within the dosing and pharmacokinetics evidence base is the absence of corroborating data from other independent analyses within this curated corpus, as the Chen 2026 network meta-analysis represents the sole source of agent-specific safety quantification for intestinal obstruction. By contrast, the broader SGLT2 inhibitor literature has emphasized cardiovascular and renal benefits, with gastrointestinal safety receiving comparatively less systematic attention. The specific finding for canagliflozin raises questions about whether this signal persists across different study populations, durations of exposure, and comparator definitions. Establishing the boundary conditions for this pharmacokinetic safety signal — including whether it is dose-dependent or attenuated with longer follow-up — remains an important unresolved question for the field."},{"id":"source_1","type":"source","study":"Movila 2026","year":2026,"doi":"10.3390/ijms27073168","url":"https://doi.org/10.3390/ijms27073168","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced all-cause mortality in studies with follow-up of up to one year (RR = 0.89, 95% CI [0.80-0.99], p = 0.03). Furthermore, long-term follow-up beyond one year showed a significant reduction in all-cause mortality (RR = 0.89, 95% CI [0.85-0.94], p < 0.0001), particularly among patients with chronic heart failure, chronic kidney disease (CKD), and diabetes mellitus (DM) with established cardiovascular disease (CVD) (following sensitivity analyses)."},{"id":"source_2","type":"source","study":"Borges 2024","year":2024,"doi":"10.1155/2024/6295345","url":"https://doi.org/10.1155/2024/6295345","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Reduction in HbA 1 C (MD = -0.93; 95% CI = -1.36 to -0.49; p < 0.0001; I 2 = 0%) was significantly higher in SGLT2i group compared with placebo. The proportion of patients requiring rescue or discontinuation of study medication due to lack of efficacy was statistically lower in SGLT2i group compared with placebo (RR = 0.64; 95% CI = 0.43-0.94; p = 0.02; I 2 = 0%)."},{"id":"source_3","type":"source","study":"Jansz 2026","year":2026,"doi":"10.1007/s00125-025-06577-2","url":"https://doi.org/10.1007/s00125-025-06577-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas."},{"id":"source_4","type":"source","study":"Ali 2026","year":2026,"doi":"10.1007/s00228-025-03985-6","url":"https://doi.org/10.1007/s00228-025-03985-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 48 h, SGLT2 inhibitors users demonstrated a smaller rise in creatinine compared with non-users (-0.04 ± 0.158 mg/dL vs. Diuretics were associated with greater increases ( p < 0.05)."},{"id":"source_5","type":"source","study":"Cersosimo 2025","year":2025,"doi":"10.2459/JCM.0000000000001733","url":"https://doi.org/10.2459/JCM.0000000000001733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At 6 months, it significantly increased to 1.40 ± 0.34 ( P < 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 ( P < 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months)."},{"id":"source_6","type":"source","study":"Omori 2026","year":2026,"doi":"10.1111/jdi.70240","url":"https://doi.org/10.1111/jdi.70240","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Patients with type 2 diabetes who were initiated on oral semaglutide or SGLT2is and continued treatment for 6 months or more were retrospectively analyzed and compared. The semaglutide group (84 patients) and the SGLT2is group (231 patients) showed similar, significant reductions in glycated hemoglobin (HbA1c) (semaglutide: -0.88 ± 0.14%; P < 0.01, and SGLT2is: -0.86 ± 0.06%; P < 0.01, at 6 months), body weight (semaglutide: -2.58 ± 0.37 kg; P < 0.01, and SGLT2is: -2.30 ± 0.18 kg; P < 0.01, at 6 months), and fat mass (semaglutide: -2.20 ± 0.50 kg; P < 0.01, and SGLT2is: -1.93 ± 0.44 kg; P < 0.01, at 6 months), being decreased similarly and significantly in both groups."},{"id":"source_7","type":"source","study":"Jiang 2022","year":2022,"doi":"10.3389/fendo.2022.802992","url":"https://doi.org/10.3389/fendo.2022.802992","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"In direct comparison, treatment with dapagliflozin 5mg showed significantly lower risk of all-cause mortality compared with treatment with dapagliflozin 2.5mg (OR 0.09, 95% CI 0.01-0.70). According to NMA, interestingly, empagliflozin 10mg/25mg, and canagliflozin 100mg was associated with significantly lower risks of all-cause mortality compared with placebo (OR of 0.70, 95% CI 0.58-0.85; 0.69, 95% CI 0.57-0.84; and 0.83, 95% CI 0.73-0.95, respectively)."},{"id":"source_8","type":"source","study":"Balbaa 2026","year":2026,"doi":"10.1002/edm2.70180","url":"https://doi.org/10.1002/edm2.70180","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Due to considerable heterogeneity, the primary pooled analysis revealed no significant association between SGLT2 inhibitor use and either eKA (OR 4.86; p = 0.11) or DKA (OR 2.21; p = 0.11). However, a significant increase in the risk of eKA (OR 1.11; p < 0.001) and DKA (OR 5.33; p < 0.001) was observed using leave‐one‐out sensitivity analysis to identify outliers."},{"id":"source_9","type":"source","study":"Vargas-Brochero 2025","year":2025,"doi":"10.1093/ndt/gfaf197","url":"https://doi.org/10.1093/ndt/gfaf197","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Patients with normal BMI did not experience the expected early decrease in eGFR ( P = .16). SGLT2is are ineffective in proteinuria reduction in patients with a BMI <25 kg/m 2 , which contrasts with the significant proteinuria reduction in overweight and obese patients with glomerulopathies."},{"id":"source_10","type":"source","study":"Xiong 2026","year":2026,"doi":"10.3389/fendo.2026.1785329","url":"https://doi.org/10.3389/fendo.2026.1785329","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"However, previous evidence shows only marginal hemoglobin A1c (HbA1c) reduction (≈0.08-0.18%) with high doses, raising uncertainty about their clinical necessity. Seventeen studies (n = 7,021) were stratified by HbA1c, and eight (n = 7,998) by GFR."},{"id":"source_11","type":"source","study":"Huang 2026","year":2026,"doi":"10.2147/DDDT.S580640","url":"https://doi.org/10.2147/DDDT.S580640","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Patients were split into the SGLT2i group (106 cases, 10mg daily dapagliflozin/empagliflozin) and the control group (324 cases). Kaplan-Meier analysis demonstrated higher 12-month AF-free survival in the SGLT2i group (total cohort Log-rank P = 0.019; PSM cohort Log-rank P = 0.016)."},{"id":"source_12","type":"source","study":"Sayour 2024","year":2024,"doi":"10.1038/s41598-024-52331-w","url":"https://doi.org/10.1038/s41598-024-52331-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"However, lower SGLT2 selectivity correlated with significantly lower risk of stroke (pseudo-R 2 = 78%; p = 0.011). Indeed, dual SGLT1/2 inhibitors significantly reduced the risk of stroke (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.64-0.94), unlike selective agents (p for interaction = 0.018)."},{"id":"source_13","type":"source","study":"Geum 2026","year":2026,"doi":"10.1155/jdr/8540354","url":"https://doi.org/10.1155/jdr/8540354","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors led to a significantly greater reduction in HbA1c (mean difference [MD]: -0.59% and 95% confidence interval [CI]: -0.91 to -0.26) and body mass index (MD: -0.82 kg/m 2 and 95% CI: -1.54 to -0.10) compared to controls. The risks of dialysis (odds ratio [OR]: 0.50 and 95% CI: 0.31-0.79), major adverse cardiovascular events (OR: 0.29 and 95% CI: 0.22-0.38), heart failure (OR: 0.66 and 95% CI: 0.52-0.83), urinary tract infection (OR: 0.45 and 95% CI: 0.22-0.92), graft rejection (OR: 0.73, 95% and CI: 0.64-0.83), and all‐cause mortality (OR: 0.40 and 95% CI: 0.27-0.59) were significantly lower in the SGLT2 inhibitor group."},{"id":"source_14","type":"source","study":"Suciu 2025","year":2025,"doi":"10.3390/medicina61101866","url":"https://doi.org/10.3390/medicina61101866","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Initiation of SGLT2 inhibitors after ACS was associated with a significant reduction in the primary outcome of all-cause mortality [hazard ratio (HR) = 0.77; (95% confidence interval (CI): 0.67-0.89)] and CV mortality [HR = 0.83; (95% CI: 0.70-0.99)]. In subgroup analyses, patients with T2DM experienced a significant reduction in all-cause mortality [HR = 0.73, (95% CI: 0.62-0.86)] and recurrent MI [HR = 0.83, (95% CI: 0.69-0.99)]."},{"id":"source_15","type":"source","study":"Wang 2026","year":2026,"doi":"10.3389/fphar.2026.1644757","url":"https://doi.org/10.3389/fphar.2026.1644757","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Compared with placebo therapy, SGLT2i significantly reduced cardiovascular death and hospitalization for HF (HHF) in both HFrEF and HFmrEF/HFpEF patients (approximately 13%-27% risk reduction). Sacubitril/valsartan demonstrated significant benefits in HFrEF patients, reducing cardiovascular death by 19%, all-cause mortality by 22%, and HHF by 22%."},{"id":"source_16","type":"source","study":"Kaze 2022","year":2022,"doi":"10.1186/s12933-022-01476-x","url":"https://doi.org/10.1186/s12933-022-01476-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Random-effects meta-analysis models were used to estimate pooled hazard ratios (HR) and 95% confidence intervals (CI) for clinical outcomes including major adverse cardiovascular events (MACE: myocardial infarction [MI], stroke, and cardiovascular death), kidney composite outcomes (a combination of worsening kidney function, end-stage kidney disease, or death from renal or cardiovascular causes), hospitalizations for heart failure (HHF), deaths and safety events (mycotic infections, diabetic ketoacidosis [DKA], volume depletion, amputations, fractures, urinary tract infections [UTI], acute kidney injury [AKI], and hyperkalemia). SGLT2i were associated with reduced risks of MACE (HR 0.83, 95% CI 0.75-0.93), kidney composite outcomes (HR 0.66, 95% CI 0.58-0.75), HHF (HR 0.62, 95% CI 0.55-0.71), cardiovascular death (HR 0.84, 95% CI 0.74-0.96), MI (HR 0.78, 95% CI 0.67-0.92), stroke (HR 0.7"},{"id":"source_17","type":"source","study":"Deng 2026","year":2026,"doi":"10.31083/RCM45590","url":"https://doi.org/10.31083/RCM45590","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Early use of SGLT2 inhibitors in hospitalized patients with acute heart failure was associated with a reduction in the incidence of composite events in the short term (relative risk (RR) = 0.64, 95% confidence interval (CI) (0.56, 0.74)), all-cause mortality (RR = 0.72, 95% CI (0.60, 0.86)), and heart failure rehospitalization rates (RR= 0.77, 95% CI (0.63, 0.87)); however, the early use of SGLT2i did not improve the incidence of cardiogenic death (RR = 0.74, 95% CI (0.51, 1.08)). Additionally, the early administration of SGLT2 inhibitors significantly reduced the incidence of cardiogenic mortality (RR = 0.77, 95% CI (0.60, 1.0); p = 0.045), as well as decreasing heart failure rehospitalization rates (RR = 0.77, 95% CI (0.70, 0.86)) and all-cause mortality (RR = 0.49, 95% CI (0.41, 0.60)), without increasing the incidence of adverse drug reactions such as acute kidney injury, urinary tra"},{"id":"source_18","type":"source","study":"Zhang 2023","year":2023,"doi":"10.3389/fendo.2023.1203666","url":"https://doi.org/10.3389/fendo.2023.1203666","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced weight-related changes and fat-related changes, including body weight(BW) (WMD= -2.74, 95% CI: -3.26 to -2.23, P<0.01), body mass index(BMI) (WMD= -0.72, 95% CI: -0.95 to -0.49, P<0.01), waist circumference(WC) (WMD= -1.60, 95% CI: -2.99 to -0.22, P=0.02), fat mass(FM)(WMD= -1.49, 95% CI: -2.18 to -0.80, P<0.01), percentage body fat(PBF) (WMD= -1.28, 95% CI: -1.83 to -0.74, P<0.01), visceral fat area(VFA)(WMD= -19.52, 95% CI: -25.90 to -13.14, P<0.01), subcutaneous fat area(SFA)(WMD= -19.11, 95% CI: -31.18 to -7.03, P=0.002), In terms of muscle-related changes, lean mass(LM)(WMD= -0.80, 95% CI: -1.43 to -0.16, P=0.01), and skeletal muscle mass(SMM) (WMD= -0.38, 95% CI: -0.65 to -0.10, P=0.007), skeletal muscle index(SMI) (WMD= -0.12, 95% CI: -0.22 to -0.02, P=0.02)were also significantly reduced. In addition, body water likewise decreased significan"},{"id":"source_19","type":"source","study":"Loutati 2026","year":2026,"doi":"10.1093/ehjcvp/pvag018","url":"https://doi.org/10.1093/ehjcvp/pvag018","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Significant TR was independently associated with worse outcomes [adjusted HR (aHR) 1.21, 95% CI 1.14-1.28, P < 0.001] while SGLT2i use was associated with lower event rates (aHR 0.79, 95% CI 0.69-0.92; P = 0.002), with consistent associations across TR strata (aHR 0.65 with vs. SGLT2i was also associated with 28% reduced risk for TR progression (95% CI 0.58-0.90; P < 0.001)."},{"id":"source_20","type":"source","study":"Chen 2024","year":2024,"doi":"10.1186/s12933-023-02042-9","url":"https://doi.org/10.1186/s12933-023-02042-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"The SGLT2 inhibitors group exhibited a significant reduction in pro b-type natriuretic peptide (NT-proBNP) levels by 136.03 pg/ml (95% confidence interval [CI]: -253.36, - 18.70; P = 0.02). Additionally, a greater proportion of patients in the SGLT2 inhibitors group showed a ≥ 20% decrease in NT-proBNP (RR = 1.45, 95% CI [0.92, 2.29], p = 0.072)."},{"id":"source_21","type":"source","study":"Colombijn 2025","year":2025,"doi":"10.1007/s00125-025-06565-6","url":"https://doi.org/10.1007/s00125-025-06565-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Risk ratios (RRs) and 95% CIs were pooled in random effects meta-analyses. In cohort studies, combination therapy was associated with a lower risk of MACE (RR 0.56 [95% CI 0.43, 0.71]; low certainty of evidence) and the kidney composite endpoint (RR 0.48 [95% CI 0.32, 0.73]; very low certainty of evidence) relative to SGLT2 inhibitor or GLP-1 RA monotherapy."},{"id":"source_22","type":"source","study":"Kumari 2026","year":2026,"doi":"10.1002/edm2.70174","url":"https://doi.org/10.1002/edm2.70174","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors were associated with a significantly lower risk of all‐cause dementia (HR = 0.74; 95% CI: 0.62-0.87), Alzheimer's disease (HR = 0.62; 95% CI: 0.52-0.74), and vascular dementia (HR = 0.54; 95% CI: 0.49-0.60) compared to DPP‐4 inhibitors. For example, Shin et al. reported a 35% lower dementia risk among younger adults using SGLT2i, while Abdullah et al. found no significant difference overall between SGLT2i and DPP‐4i users, with the association reaching significance only in older adults [ 12 , 15 ]."},{"id":"source_23","type":"source","study":"Teng 2026","year":2026,"doi":"10.3389/fcdhc.2026.1775359","url":"https://doi.org/10.3389/fcdhc.2026.1775359","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated. SGLT2 inhibitors did not increase overall cancer risk (RR = 1.05, 95% CI [0.99, 1.12])."},{"id":"source_24","type":"source","study":"Park 2026","year":2026,"doi":"10.1136/bmjopen-2025-105271","url":"https://doi.org/10.1136/bmjopen-2025-105271","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Patients aged 40 years or older who were newly prescribed either SGLT2 inhibitors or TZDs without prior exposure. After a 1:1 propensity score matching, the SGLT2 inhibitors showed no significant difference in stroke risk (HR 1.18, 95% CI 0.62 to 2.23, p=0.62), while having significant reductions in dementia risk (HR 0.66, 95% CI 0.45 to 0.98, p=0.04) and AD risk (HR 0.54, 95% CI 0.35 to 0.83, p=0.005)."},{"id":"source_25","type":"source","study":"Andersson 2026","year":2026,"doi":"10.1136/bmjopen-2025-110395","url":"https://doi.org/10.1136/bmjopen-2025-110395","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Use of SGLT2i and GLP-1 RA declined with age (p<0.001). However, increased use of SGLT2i and GLP-1 RA has been seen in patients under 80 years of age with T2D who have recently experienced a myocardial infarction."},{"id":"source_26","type":"source","study":"Duman 2025","year":2025,"doi":"10.1186/s12872-025-05308-0","url":"https://doi.org/10.1186/s12872-025-05308-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"This observational, cross-sectional study included 134 patients with HF and EF < 50%, divided into two groups: those receiving SGLT2 inhibitors (SGLT2+, n = 25) and those not receiving them (SGLT2-, n = 109). The prevalence of diabetes mellitus, spironolactone use, and furosemide use was significantly higher in the SGLT2 + group (all p < 0.05)."},{"id":"source_27","type":"source","study":"Hung 2025","year":2025,"doi":"10.1097/JS9.0000000000003450","url":"https://doi.org/10.1097/JS9.0000000000003450","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"A dose-stratified analysis revealed that high-dose injectable semaglutide (2.4 mg/week) was the only regimen associated with increased incidence. Our study provides the first comprehensive NMA addressing the incidence of colorectal tumors related to individual GLP-1 receptor agonists and SGLT2 inhibitors, suggesting a dose-dependent relationship to semaglutide, particularly in its high-dose injectable form (2.4 mg/week)."},{"id":"source_28","type":"source","study":"Darba 2026","year":2026,"doi":"10.1007/s40273-026-01611-6","url":"https://doi.org/10.1007/s40273-026-01611-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Chronic kidney disease is a progressive condition that affects more than 10% of the global population, corresponding to over 800 million individuals worldwide [ 1 ]. According to the World Health Organization, kidney diseases ranked as the seventh leading cause of death among non-communicable diseases in 2021, with mortality increasing by 95% since 2000 [ 2 ]."},{"id":"source_29","type":"source","study":"Teo 2021","year":2021,"doi":"10.1161/JAHA.120.019463","url":"https://doi.org/10.1161/JAHA.120.019463","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"In patients without diabetes mellitus, those with heart failure treated with SGLT2 inhibitors had a 20% relative risk reduction in cardiovascular deaths and heart failure hospitalizations, compared with those who were not treated (risk ratio, 0.78; P <0.001). Patients on SGLT2 inhibitors had a reduction in body weight of -1.21 kg ( P <0.001), body mass index of -0.47 kg/m 2 ( P <0.001), systolic blood pressure of -1.90 mm Hg ( P =0.04), and fasting plasma glucose of -0.38 mmol/L ( P =0.05), compared with those without."},{"id":"source_30","type":"source","study":"Chen 2023","year":2023,"doi":"10.3389/fendo.2023.1236404","url":"https://doi.org/10.3389/fendo.2023.1236404","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In CKD patients, SGLT2 inhibitors reduced the risk of cardiovascular death (CVD) or hospitalization for heart failure (HHF) by 28%, CVD by 16%. and HHF by 35%. They also reduced the risk of all-cause death by 14% without increasing the risk of serious adverse effects (SAEs) and urinary tract infections (UTIs)."},{"id":"source_31","type":"source","study":"E 2026","year":2026,"doi":"10.1155/jdr/6584068","url":"https://doi.org/10.1155/jdr/6584068","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"SGLT2 inhibitors consistently reduced HF hospitalisation rates in real‐world use (pooled HR 0.65, 95% CI 0.59-0.72). The absolute risk reduction for hospitalisation for HF in people with a history of CVD (ARR 1.17, 95% CI 0.78-1.55) was significantly greater than for those without CVD (ARR 0.39, 95% CI 0.32-0.47)."},{"id":"source_32","type":"source","study":"Salvatore 2022","year":2022,"doi":"10.3390/ijms23073651","url":"https://doi.org/10.3390/ijms23073651","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"SGLT2-Is reduce the renal threshold for glucose excretion from about 10 mmol/L (180 mg/dL) to 2.2 mmol/L (40 mg/dL) [ 2 ]. However, the CV benefits observed in several studies aroused great interest in their therapeutic advantages, which go beyond the glycemic control and prompted the design of a series of CV outcome trials (CVOTs) conducted during the past 6 years."},{"id":"source_33","type":"source","study":"Neuen 2026","year":2026,"doi":"10.1001/jama.2025.20834","url":"https://doi.org/10.1001/jama.2025.20834","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Study selection Randomized, double-blind, placebo-controlled trials within SMART-C evaluating an SGLT2 inhibitor with label indications for reducing CKD progression including at least 500 participants in each group with at least 6 months of follow-up. SGLT2 inhibitors reduced the risk of CKD progression (25.4 vs 40.3 events per 1000 patient-years; hazard ratio [HR], 0.62 [95% CI, 0.57-0.68]), irrespective of baseline eGFR (HR of 0.61 [95% CI, 0.52-0.71] for eGFR ≥60 mL/min/1.73 m2; 0.57 [95% CI, 0.47-0.70] for eGFR of 45 to <60 mL/min/1.73 m2; 0.64 [95% CI, 0.54-0.75] for eGFR of 30 to <45 mL/min/1.73 m2; and 0.71 [95% CI, 0.60-0.83] for eGFR <30 mL/min/1.73 m2; P for trend = .16) and baseline albuminuria (HR of 0.58 [95% CI, 0.44-0.76] for albuminuria ≤30 mg/g; 0.74 [95% CI, 0.57-0.96] for >30-300 mg/g; and 0.57 [95% CI, 0.52-0.64] for more than 300 mg/g; P for trend = .49)."},{"id":"source_34","type":"source","study":"Cho 2025","year":2025,"doi":"10.1371/journal.pone.0314454","url":"https://doi.org/10.1371/journal.pone.0314454","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Over a median follow-up of 31 months, patients on SGLT2 inhibitors were associated with a lower risk of hospitalizations for HF or mortality compared to those on DPP4 inhibitors (HR 0.61; 95% CI 0.44-0.85; P = 0.004). SGLT2 inhibitor use was also associated with a lower risk of mortality (HR 0.61; 95% CI 0.39-0.94; P = 0.025) and CV mortality (HR 0.43; 95% CI 0.21-0.86; P = 0.018), but not of MI (HR 1.22 [95% CI 0.72-2.09]; P = 0.461) or stroke (HR 1.00 [95% CI 0.75-1.33]; P = 0.980)."},{"id":"source_35","type":"source","study":"Daniyal 2026","year":2026,"doi":"10.1002/edm2.70184","url":"https://doi.org/10.1002/edm2.70184","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random‐effects model. SGLT2 inhibitor use was associated with a reduced risk of the composite outcome (HR: 0.75; 95% CI: 0.65, 0.86; p < 0.01)."},{"id":"source_36","type":"source","study":"Chen 2026","year":2026,"doi":"10.3390/ijms27020608","url":"https://doi.org/10.3390/ijms27020608","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Overall, canagliflozin use was associated with a higher incidence of intestinal obstruction than control therapies (OR 2.56, 95% CI 1.01-6.49), corresponding to an absolute risk difference of 0.15% and a number needed to harm of 658. In contrast, liraglutide was associated with a lower risk of intestinal obstruction (OR 0.44, 95% CI 0.24-0.81), with an absolute risk reduction of 0.34% and a number needed to treat of 295."},{"id":"source_37","type":"source","study":"Hu 2026","year":2026,"doi":"10.3389/fmed.2026.1768225","url":"https://doi.org/10.3389/fmed.2026.1768225","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Although U.S. corresponding authors contributed 267 papers, their share of multiple country publications (MCP) reached 39.7%, significantly higher than China’s 7.6%, underscoring the U.S.’s stronger engagement in international collaborative research ( Figure 3A ). An analysis of the top 10 journals publishing research on SGLT2 inhibitors in kidney disease revealed that they collectively accounted for 23.25% of all publications, with a total of 363 articles ( Figure 5A )."},{"id":"source_38","type":"source","study":"Schonberger 2023","year":2023,"doi":"10.3390/ijerph20176671","url":"https://doi.org/10.3390/ijerph20176671","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"A systematic review and meta-analysis of cardiovascular outcome studies, which assessed how SGLT2 inhibitors affected the incidence of major cardiovascular events (MACEs) in T2D patients categorized by age, found that age has no effect on the effectiveness profile of SGLT2 inhibitors versus placebo, with a hazard ratio (HR) of 0.83 (95% confidence interval [CI], 0.71-0.96) for those ≥65 years [ 31 ]. Post hoc analyses of various cardiovascular outcome trials, including the EMPA-REG OUTCOME with empagliflozin [ 36 ], DECLARE-TIMI 58 with dapagliflozin [ 37 ], and VERTIS CV with ertugliflozin [ 38 ], revealed that SGLT2 inhibitors generally had the same efficacy and safety profile across different age ranges (<65 years vs. ≥65 to <75 years, and ≥75 years)."},{"id":"source_39","type":"source","study":"Joongpan 2026","year":2026,"doi":"10.1002/prp2.70232","url":"https://doi.org/10.1002/prp2.70232","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduced body weight (standardized mean difference (SMD) = -0.85, p < 0.001; I2 = 0%) and fat mass (SMD = -0.53, p < 0.001; I2 = 51.1%). A small reduction in muscle mass was observed (SMD = -0.35, p < 0.001; I2 = 22.9%), though substantially smaller than fat loss."},{"id":"source_40","type":"source","study":"Neuen 2024","year":2024,"doi":"10.1161/circulationaha.124.071689","url":"https://doi.org/10.1161/circulationaha.124.071689","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Kidney outcomes included a composite of ≥50% reduction in estimated glomerular filtration rate, kidney failure or death caused by kidney failure, and annualized rate of decline in estimated glomerular filtration rate (estimated glomerular filtration rate slope). GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events by 21% (hazard ratio [HR], 0.79 [95% CI, 0.71-0.87]), with consistent effects in those receiving and not receiving SGLT2 inhibitors at baseline (HR, 0.77 [95% CI, 0.54-1.09] and HR, 0.79 [95% CI, 0.71-0.87], respectively; P -heterogeneity=0.78)."},{"id":"source_41","type":"source","study":"Zou 2019","year":2019,"doi":"10.1097/MD.0000000000018245","url":"https://doi.org/10.1097/MD.0000000000018245","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Type 2 diabetes (T2DM), one of the most severe public health disorders, had a worldwide prevalence of 10% in the general population and affected more than 415 million adults in 2013, and this number has been projected to increase to 592 million by 2035. [ 1 , 2 ] Cardiovascular disease, a serious complication of type 2 diabetes, is primarily associated with excess mortality and morbidity in these patients. [ 3 ] More than 70% of type 2 diabetes patients die of cardiovascular causes. [ 4 ] The main contributors to the increased risk of cardiovascular disease include chronic hyperglycemia, insulin sensitivity reduction, visceral adiposity, and in particular, the comorbidities of hypertension and increased arterial stiffness. [ 5 ] Existing antidiabetic agents (ADAs) lower blood glucose either by enhancing insulin secretion or by improving insulin sensitivity. Sodium-glucose cotransporter-2"},{"id":"source_42","type":"source","study":"Baker 2017","year":2017,"doi":"10.1161/JAHA.117.005686","url":"https://doi.org/10.1161/JAHA.117.005686","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"SGLT2 inhibitors significantly reduce 24‐hour ambulatory systolic and diastolic BP by -3.76 mm Hg (95% CI, -4.23 to -2.34; I 2 =0.99) and -1.83 mm Hg (95% CI, -2.35 to -1.31; I 2 =0.76), respectively. A recent meta‐analysis of 27 randomized controlled trials (RCTs) concluded that, in patients with type 2 diabetes mellitus, SGLT2 inhibitors improve systolic BP by -4 mm Hg (95% CI, -4.4 to -3.5) and diastolic BP by -1.6 mm Hg (95% CI, -1.9 to -1.3)."}],"edges":[{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_1","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_2","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_3","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_4","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_5","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_6","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_7","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_8","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_9","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_10","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_11","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_12","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_13","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_14","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_15","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_16","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_17","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_18","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_19","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_20","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_21","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_22","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_23","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_24","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_25","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_26","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_27","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_28","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_29","type":"contains_claim"},{"from":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","to":"claim_30","type":"contains_claim"}],"screening":{"identified":42,"screened":42,"excluded":0,"included":42,"included_or_retained":42,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"42 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","screening":{"identified":42,"screened":42,"excluded":0,"included":42,"included_or_retained":42,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"42 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed the management of type 2 diabetes and heart failure, yet their potential effects across broader aging-related outcomes—mortality, cognition, sarcopenia, and long-term safety—remain incompletely characterized. This structured evidence synthesis applied structured corpus search, data extraction, and quality appraisal methods to 42 reference papers spanning meta-analyses, observational cohorts, and mechanistic studies, with an explicit audit trail documenting inclusion decisions and analytic choices. Heart failure hospitalization was consistently reduced in real-world settings, with a pooled HR of 0.65 (95% CI 0.59–0.72), and in chronic kidney disease patients, SGLT2 inhibitors reduced cardiovascular death or hospitalization for heart failure by approximately one-quarter (28%) and hospitalization for heart failure by 35% (E 2026; Chen 2023).","In sum, the evidence supports class-level cardiorenal and mortality benefits of SGLT2 inhibitors that extend beyond glycemic control, yet the anti-aging case remains incomplete: cognitive and sarcopenia data are sparse, most longevity outcomes derive from post-hoc or observational designs rather than dedicated aging-focused RCTs, and the balance between metabolic benefit and lean-mass loss requires longitudinal characterization before SGLT2 inhibitors can be recommended for healthy aging outside their indications.","The corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 17 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.","The thesis is: Across 42 curated reference papers, the evidence base for Sglt2 Inhibitors Effects shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes The Sglt2 Inhibitors Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","Another tension arises between the neuroprotective and dementia-risk reduction signals of SGLT2 inhibitors and the absence of mechanistic clarity regarding how renal glucose excretion could protect the brain. This is a severity-5 disagreement within the contextual other outcome class. The mechanistic challenge is substantial: unlike cardiovascular benefits, which can be attributed to hemodynamic effects (preload reduction, afterload reduction, improved myocardial energetics via ketone body utilization), no established pathway connects renal glucose excretion to reduced amyloid deposition, tau phosphorylation, or neuroinflammation. Schonberger 2023 discusses immunomodulatory and anti-inflammatory effects of SGLT2 inhibitors, which could theoretically attenuate neuroinflammation, but this remains speculative without brain-specific biomarker data. The boundary condition for this tension is likely confounding by indication and healthy-user bias: patients prescribed SGLT2 inhibitors tend to have better metabolic profiles and more intensive overall diabetes management, which are themselves protective against cognitive decline. The evidence needed to resolve this tension includes Mendelian randomization studies using genetic instruments for SGLT2 activity and brain MRI biomarker endpoints in SGLT2 inhibitor trials, neither of which currently exist in the literature."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nMovila 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nBorges 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nJansz 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAli 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nCersosimo 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nOmori 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nJiang 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nBalbaa 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nVargas-Brochero 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nXiong 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nHuang 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSayour 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nGeum 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSuciu 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nWang 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nKaze 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nDeng 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZhang 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLoutati 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nChen 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nColombijn 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nKumari 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nTeng 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nPark 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAndersson 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDuman 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nHung 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nDarba 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nTeo 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nChen 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nE 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSalvatore 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNeuen 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nCho 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDaniyal 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nChen 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nHu 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSchonberger 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nJoongpan 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nNeuen 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZou 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBaker 2017,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"f0b4aa8b-f260-4fc6-8419-dac0b0a34715","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Movila 2026","doi":"10.3390/ijms27073168","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Borges 2024","doi":"10.1155/2024/6295345","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Jansz 2026","doi":"10.1007/s00125-025-06577-2","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Ali 2026","doi":"10.1007/s00228-025-03985-6","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Cersosimo 2025","doi":"10.2459/JCM.0000000000001733","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Omori 2026","doi":"10.1111/jdi.70240","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Jiang 2022","doi":"10.3389/fendo.2022.802992","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Balbaa 2026","doi":"10.1002/edm2.70180","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Vargas-Brochero 2025","doi":"10.1093/ndt/gfaf197","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Xiong 2026","doi":"10.3389/fendo.2026.1785329","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Huang 2026","doi":"10.2147/DDDT.S580640","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sayour 2024","doi":"10.1038/s41598-024-52331-w","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Geum 2026","doi":"10.1155/jdr/8540354","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Suciu 2025","doi":"10.3390/medicina61101866","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Wang 2026","doi":"10.3389/fphar.2026.1644757","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Kaze 2022","doi":"10.1186/s12933-022-01476-x","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Deng 2026","doi":"10.31083/RCM45590","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zhang 2023","doi":"10.3389/fendo.2023.1203666","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Loutati 2026","doi":"10.1093/ehjcvp/pvag018","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Chen 2024","doi":"10.1186/s12933-023-02042-9","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Colombijn 2025","doi":"10.1007/s00125-025-06565-6","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Kumari 2026","doi":"10.1002/edm2.70174","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Teng 2026","doi":"10.3389/fcdhc.2026.1775359","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Park 2026","doi":"10.1136/bmjopen-2025-105271","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Andersson 2026","doi":"10.1136/bmjopen-2025-110395","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Duman 2025","doi":"10.1186/s12872-025-05308-0","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Hung 2025","doi":"10.1097/JS9.0000000000003450","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Darba 2026","doi":"10.1007/s40273-026-01611-6","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Teo 2021","doi":"10.1161/JAHA.120.019463","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Chen 2023","doi":"10.3389/fendo.2023.1236404","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"E 2026","doi":"10.1155/jdr/6584068","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Salvatore 2022","doi":"10.3390/ijms23073651","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Neuen 2026","doi":"10.1001/jama.2025.20834","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Cho 2025","doi":"10.1371/journal.pone.0314454","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Daniyal 2026","doi":"10.1002/edm2.70184","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Chen 2026","doi":"10.3390/ijms27020608","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Hu 2026","doi":"10.3389/fmed.2026.1768225","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Schonberger 2023","doi":"10.3390/ijerph20176671","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Joongpan 2026","doi":"10.1002/prp2.70232","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Neuen 2024","doi":"10.1161/circulationaha.124.071689","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zou 2019","doi":"10.1097/MD.0000000000018245","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Baker 2017","doi":"10.1161/JAHA.117.005686","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}]}}]}